Author: Li, Lv; Dai, Hong-Juan; Ye, Mao; Wang, Shu-Ling; Xiao, Xiao-Juan; Zheng, Jie; Chen, Hui-Yong; Luo, Yu-hao; Liu, Jing
Title: Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition Document date: 2012_11_23
ID: 13amcxh2_1
Snippet: Leukemia is a type of fatal hematological malignancy. Human chronic myelocytic leukemia (CML), a common type of leukemia, is a myeloproliferative disorder characterized by increased proliferation of granulocytic cell lines with loss capacity to differentiate. CML originates from a constitutive activation of Bcr-Abl tyrosine kinase, which develops from Philadelphia chromosome translocation. Imatinib mesylate (Glivec), a selective inhibitor of Bcr-.....
Document: Leukemia is a type of fatal hematological malignancy. Human chronic myelocytic leukemia (CML), a common type of leukemia, is a myeloproliferative disorder characterized by increased proliferation of granulocytic cell lines with loss capacity to differentiate. CML originates from a constitutive activation of Bcr-Abl tyrosine kinase, which develops from Philadelphia chromosome translocation. Imatinib mesylate (Glivec), a selective inhibitor of Bcr-Abl, was developed as the first moleculetargeted anticancer drug to treat CML patients. However, many patients report developing resistance to Glivec due to mutations in the Abl kinase domain [1, 2] . Considering the difficulties inherent in the current CML therapy, the discovery and development new treatment approaches for CML treatment remains an urgent necessity.
Search related documents:
Co phrase search for related documents- Abl kinase and Bcr Abl selective inhibitor: 1
- Abl kinase and CML patient: 1
- Abl kinase and CML treatment: 1
- Abl kinase and Imatinib mesylate: 1
- Abl kinase and selective inhibitor: 1
- Abl kinase and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- Abl kinase domain and tyrosine kinase: 1
- Abl tyrosine kinase and Bcr Abl selective inhibitor: 1
- Abl tyrosine kinase and CML patient: 1
- Abl tyrosine kinase and Imatinib mesylate: 1
- Abl tyrosine kinase and selective inhibitor: 1
- Abl tyrosine kinase and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- anticancer drug and cell line: 1, 2, 3, 4, 5, 6
- anticancer drug and CML therapy: 1
- anticancer drug and development discovery: 1, 2
- anticancer drug and tyrosine kinase: 1, 2, 3, 4, 5, 6
- Bcr Abl selective inhibitor and selective inhibitor: 1
- Bcr Abl selective inhibitor and tyrosine kinase: 1
Co phrase search for related documents, hyperlinks ordered by date